Amgen (AMGN) Tops Q1 EPS by 38c; Boosts FY15 Outlook

Amgen (NASDAQ: AMGN) reported Q1 EPS of $2.48, $0.38 better than the analyst estimate of $2.10. Revenue for the quarter came in at $5.03 billion versus the consensus estimate of $4.91 billion.

Amgen sees FY2015 EPS of $9.35 - $9.65, versus the consensus of $9.32. Amgen sees FY2015 revenue of $20.9 - $21.3 billion, versus the consensus of $20.98 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Redburn starts Mettler-Toledo at Sell, sees valuation outpacing growth
• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance